New Antibody For EGFR Causes Lung Cancer Regression

Main Category: Lung Cancer
Article Date: 30 Jan 2007 - 5:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  

Current Article Ratings:

Patient / Public:5 stars

5 (4 votes)

Healthcare Prof:5 stars

5 (1 votes)


Mutant forms of the protein EGFR are important for the development of lung cancer in a substantial proportion of individuals with this disease. However, not all individuals express the same mutant EGFR, for example, some have a mutation that affects the intracellular part of EGFR and some have a mutation that affects the extracellular part of EGFR (known as the EGFRvIII mutant). The potential of therapeutics to benefit individuals with lung cancer caused by the distinct EGFR mutants can be examined using two mouse models of lung cancer, one driven by expression of EGFR with a mutation in the intracellular part of the protein and one driven by expression of the EGFRvIII mutant.

In a study appearing online in advance of publication in the February print issue of the Journal of Clinical Investigation, Kwok-Kin Wong and colleagues from the Dana-Farber Cancer Institute in Boston show that a mouse antibody that binds EGFR (mAb806) causes the regression of lung tumors in both models of lung cancer. By contrast, a second antibody that binds EGFR (cetuximab), and that is already in clinical use for the treatment of a specific subset of patients with lung cancer, only induced tumor regression in mice with lung tumors driven by expression of EGFR with a mutation in the intracellular part of the protein. Importantly, the humanized form of mAb806 (ch806) caused regression of lung tumors in both models of lung cancer. The data presented in this study therefore indicate that ch806 might provide a new therapeutic for the treatment of patients with lung cancer driven by mutant forms of EGFR, in particular the EGFRvIII mutant.

TITLE: Therapeutic anti-EGFR antibody 806 generates responses in murine de novo EGFR mutant-dependent lung carcinomas

AUTHOR CONTACT:
Kwok-Kin Wong
Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.

###

JCI table of contents: January 25, 2006

Contact: Karen Honey
Journal of Clinical Investigation

Article adapted by Medical News Today from original press release.
Visit our lung cancer section for the latest news on this subject.
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:

MLA
Karen Honey. "New Antibody For EGFR Causes Lung Cancer Regression." Medical News Today. MediLexicon, Intl., 30 Jan. 2007. Web.
15 Feb. 2012. <http://www.medicalnewstoday.com/releases/61696.php>

APA
Karen Honey. (2007, January 30). "New Antibody For EGFR Causes Lung Cancer Regression." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/61696.php.

Please note: If no author information is provided, the source is cited instead.


Lung Cancer

What is Lung Cancer?

Cancer is a class of diseases characterized by out-of-control cell growth, and lung cancer occurs when this uncontrolled cell growth begins in one or both lungs. Rather than developing into healthy, normal lung tissue, these abnormal cells continue... Read more...

Most Popular Articles



Follow Our Lung Cancer News On Twitter

Follow Us On Twitter
Get the latest news for this category delivered straight to your Twitter account. Simply visit our Lung Cancer Twitter account and select the 'follow' option.



View list of all 'What Is...' articles »